siRNA组合药物JNJ-73763989在健康受试者与慢性乙型肝炎患者中的群体药代动力学
本研究基于七项临床试验的汇总数据,建立JNJ-73763989(两种GalNAc偶联siRNA)皮下给药后的群体药代动力学模型,并模拟肝脏暴露。模型显示两种siRNA呈吸收速率限制的「翻转」动力学,肝摄取由去唾液酸糖蛋白受体介导的可饱和竞争过程描述,JNJ-73763924对该受体亲和力较JNJ-73763976高2.5倍。预测治疗12个月后肝脏浓度接近稳态,2:1给药比例可维持约2:1的肝浓度比。体重、肌酐清除率、慢性乙肝状态和肝损伤与血浆药代参数相关并纳入最终模型。
要点
- 两种siRNA皮下给药后呈吸收速率限制的翻转动力学,吸收半衰期远长于血浆消除半衰期。
- 肝摄取为去唾液酸糖蛋白受体介导的可饱和竞争过程,JNJ-73763924受体亲和力高2.5倍。
- 体重、肌酐清除率、慢性乙肝和肝损伤与血浆药代参数相关并纳入最终模型。
核心结论
- JNJ-73763989两种siRNA的血浆处置可用线性二室模型加可饱和肝摄取组件描述。
- 预测2:1给药比例可维持约2:1的肝脏浓度比,治疗12个月后肝浓度接近稳态。
研究设计与样本
- 基于七项临床试验汇总数据建立群体药代动力学模型,并联合临床前信息模拟肝脏暴露。
主要发现
- 两种siRNA的吸收速率常数相似,但吸收半衰期为血浆消除半衰期的20至40倍。
- JNJ-73763924对去唾液酸糖蛋白受体的亲和力较JNJ-73763976高2.5倍。
- 预测两种siRNA的肝脏浓度在JNJ-73763989治疗12个月后接近稳态。
- 体重、肌酐清除率、慢性乙肝和肝损伤与血浆药代参数相关并纳入最终模型。
关键数值与推荐
- JNJ-73763976与JNJ-73763924的2:1给药比例预测维持约2:1的肝脏浓度比。
- JNJ-73763924对去唾液酸糖蛋白受体的亲和力为JNJ-73763976的2.5倍。
- 吸收半衰期为血浆消除半衰期的20至40倍。
临床怎么用
- 该模型提示体重、肌酐清除率、慢性乙肝和肝损伤可能影响血浆药代,临床用药时需关注这些因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JNJ-73763989 is a combination product consisting of two N-acetylgalactosamine-conjugated short-interfering RNA triggers (JNJ-73763976 and JNJ-73763924) that are in development as a potential treatment for chronic hepatitis B virus infection. A population pharmacokinetic model for JNJ-73763989 was developed based on pooled data from seven clinical studies to characterize the plasma pharmacokinetics of the short-interfering RNAs following subcutaneous administration. Additionally, simulations of liver (target organ) exposure using the final population pharmacokinetic model in conjunction with preclinical information were performed. Disposition of JNJ-73763976 and JNJ-73763924 was governed by a linear two-compartment model describing the peripheral distribution of both short-interfering RNAs and a saturable component describing liver uptake via the asialoglycoprotein receptor. While the estimated first-order absorption rate constant was similar for both short-interfering RNAs, the corresponding absorption half-life values were 20- to 40-fold longer than the estimated plasma elimination half-life for both short-interfering RNAs, indicating absorption rate-limited or "flip-flop" kinetics. Plasma-to-liver transport of each short-interfering RNA was modeled by a saturable, receptor-mediated competitive process, and the affinity for the asialoglycoprotein receptor was 2.5-fold higher for JNJ-73763924 relative to JNJ-73763976. Predicted liver concentrations of both short-interfering RNA triggers approached steady state after 12 months of JNJ-73763989 treatment. The 2:1 dosing ratio of JNJ-73763976 to JNJ-73763924 was predicted to maintain an ~2:1 liver concentration ratio, irrespective of the identified plasma disposition differences between the triggers. Body weight, creatinine clearance, presence of chronic hepatitis B, and hepatic impairment were associated with plasma pharmacokinetic parameters and were included in the final population pharmacokinetic model.
引用
- Ogawa T, Goeyvaerts N, Kakuda TN, et al. Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis B. Clin Pharmacol Ther. 2025. PMID: 40375057. doi:10.1002/cpt.3690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。